(MCRB) Seres Therapeutics - Performance 1206.4% in 12m
Compare MCRB with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
-79.26%
#43 in Group
Rel. Strength
99.95%
#5 in Universe
Total Return 12m
1206.44%
#3 in Group
Total Return 5y
124.79%
#18 in Group
P/E -
(?) Percentile in Group
P/E Forward 0.84
8th Percentile in Group
PEG -0.11
50th Percentile in Group
FCF Yield -
(?) Percentile in Group
12m Total Return: MCRB (1206.4%) vs XBI (-7.2%)

5y Drawdown (Underwater) Chart

Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
UTHR NASDAQ United Therapeutics |
-8.45% | 25.1% | 163% | 11.8 | 10.6 | 1.43 | 83.8% | 78.5% |
HLN NYSE Haleon |
3.06% | 25.7% | 43.7% | 24.7 | 20.3 | 1.8 | 27.1% | - |
AMGN NASDAQ Amgen |
-11.4% | 5.51% | 37.4% | 36.6 | 13.3 | 0.94 | -18.8% | -20% |
LONN SW Lonza |
-3.34% | 9.2% | 33.3% | 60.7 | 31.7 | 1.15 | 12.6% | -10.3% |
BIM PA Biomerieux |
-3.25% | 13.2% | -1.03% | 31 | 24.2 | 1.45 | -58.7% | -25.1% |
NBIX NASDAQ Neurocrine Biosciences |
-12% | -23.9% | 3.63% | 30.8 | 20.4 | 0.27 | 61.5% | 31.6% |
KMDA NASDAQ Kamada |
-8.87% | 30.5% | -10.1% | 24.3 | 22.8 | 0.91 | 47.7% | 3.93% |
ERF PA Eurofins Scientific SE |
-2.43% | -17.2% | 17.1% | 24.3 | 11.7 | 0.58 | -70.8% | -17.1% |
Performance Comparison: MCRB vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for MCRB
Total Return (including Dividends) | MCRB | XBI | S&P 500 |
---|---|---|---|
1 Month | 0.00% | -12.59% | -8.16% |
3 Months | 795.23% | -14.87% | -12.80% |
12 Months | 1206.44% | -7.16% | 6.85% |
5 Years | 124.79% | -19.64% | 100.40% |
Trend Score (consistency of price movement) | MCRB | XBI | S&P 500 |
1 Month | -90.8% | -52.8% | -63.5% |
3 Months | -92.3% | -92.8% | -90.3% |
12 Months | -52.4% | -32.4% | 60.6% |
5 Years | -84.0% | -53.3% | 84.2% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
1 Month | #48 | 14.4% | 8.88% |
3 Month | #1 | 952% | 927% |
12 Month | #3 | 1,307% | 1,123% |
5 Years | #17 | 180% | 12.2% |
FAQs
Does MCRB Seres Therapeutics outperforms the market?
Yes,
over the last 12 months MCRB made 1206.44%, while its related Sector, the SPDR S&P Biotech (XBI) made -7.16%.
Over the last 3 months MCRB made 795.23%, while XBI made -14.87%.
Over the last 3 months MCRB made 795.23%, while XBI made -14.87%.
Performance Comparison MCRB vs Indeces and Sectors
MCRB vs. Indices MCRB is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 1.93% | 8.16% | 952% | 1,200% |
US NASDAQ 100 | QQQ | 2.95% | 9.41% | 953% | 1,200% |
US Dow Jones Industrial 30 | DIA | 2.88% | 7.86% | 951% | 1,202% |
German DAX 40 | DAX | -0.16% | 6.86% | 933% | 1,188% |
Shanghai Shenzhen CSI 300 | CSI 300 | -1.69% | 3.73% | 949% | 1,198% |
Hongkong Hang Seng | HSI | -3.12% | 4.96% | 947% | 1,189% |
India NIFTY 50 | INDA | -4.64% | -2.65% | 946% | 1,203% |
Brasil Bovespa | EWZ | -4.02% | 1.26% | 947% | 1,216% |
MCRB vs. Sectors MCRB is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 1.77% | 8.32% | 943% | 1,191% |
Consumer Discretionary | XLY | 1.45% | 8.87% | 948% | 1,196% |
Consumer Staples | XLP | -1.49% | -3.58% | 941% | 1,194% |
Energy | XLE | -2.96% | 12.3% | 951% | 1,219% |
Financial | XLF | 0.23% | 5.96% | 942% | 1,189% |
Health Care | XLV | 1.91% | 8.22% | 953% | 1,208% |
Industrial | XLI | 1.36% | 7.19% | 951% | 1,202% |
Materials | XLB | -0.68% | 5.96% | 957% | 1,213% |
Real Estate | XLRE | -1.46% | 3.35% | 949% | 1,191% |
Technology | XLK | 4.20% | 11.6% | 959% | 1,207% |
Utilities | XLU | -0.41% | 0.22% | 945% | 1,185% |
Aerospace & Defense | XAR | 2.29% | 5.37% | 943% | 1,185% |
Biotech | XBI | -1.44% | 12.6% | 964% | 1,214% |
Homebuilder | XHB | -1.20% | 7.98% | 965% | 1,214% |
Retail | XRT | -2.28% | 5.62% | 954% | 1,211% |